TEM Stock Forecast & Price Target

Tempus AI is supported by a strengthening strategic and commercial thesis driven by the pending Personalis acquisition, which adds a differentiated tumor-informed MRD platform to its broader diagnostics stack. Positive INTerpath-001 readthrough from Merck and Moderna validates individualized neoantigen therapy, while Tempus’ FDA clearance for tumor-only xT CDx and ECG-PH expands its addressable market and reinforces the scalability of its AI-enabled product portfolio. Financially, the deal implies about 8.9x pro forma LTM EV/Revenue, with roughly 25% expected revenue growth over the next 12 months and meaningful upside from potential ASP gains, broader MRD coverage, and higher-value biopharma data licensing.

Tempus AI is exposed to a weak fundamental setup because its valuation depends on aggressive EV/Revenue assumptions and next 12 months sales per share of $9.87, while its net debt of $3.00 per share still leaves limited room for execution missteps. The business faces multiple pressure points, including slower-than-expected sales growth from competition, regulation, or technological obsolescence, along with the risk that it cannot secure approvals for new products or retain biopharma partnerships. Additional downside comes from sustainability concerns around profitability, dilution risk, and integration and reimbursement uncertainty, especially since commercial payer coverage can lag MolDX by 12–24 months and NeXT Personal remains early-stage.